Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287222 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00287222 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 21 participants.
The verdict
NCT00287222, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The primary efficacy endpoint will be the proportion of subjects that remain free of progression at the 27th week following the onset of treatment. Secondary objectives include the subject's time in weeks from treatment onset to documented disease progression as assessed by the RECIST criteria, response rate, median and overall survival, safety and tolerability.
Interventions
- DRUG Bevacizumab
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287222
The ClinicalTrials.gov registry entry for NCT00287222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00287222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287222 about?
NCT00287222 is a clinical study titled "Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma". The primary efficacy endpoint will be the proportion of subjects that remain free of progression at the 27th week following the onset of treatment. Secondary objectives include the subject's time in weeks from treatment onset to documented disease progression as assessed by the RECIST criteria, resp...
What is the current status of trial NCT00287222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2006-02. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00287222?
The interventions under investigation include: Bevacizumab (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00287222?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.